Pfizer adds shifts, invests resources to cope with surge in demand for syphilis treatment

07 Jul 2023
endpts.com
As Pfizer continues to grapple with increased demand for its antibiotic Bicillin, experts worry shortages may stoke the worsening syphilis epidemic in the US.
The pharma giant announced last month that it anticipates shortages for certain Bicillin L-A and Bicillin C-R prefilled syringes “due to an increase in syphilis infection rates as well as competitive shortages.” Bicillin is a long-acting form of penicillin commonly used to treat syphilis and is the only drug currently recommended to treat pregnant women with the sexually transmitted infection.
Pfizer adds shifts, invests resources to cope with surge in demand for syphilis treatment
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.